Remdesivir is Formulary, Restricted to approval by Infectious Diseases, as decided at the November 2024 P&T meeting.

For patients with COVID-19: Restricted to Infectious Disease approval 8 am-5pm. ID consult team will assess the patient for appropriate inclusion/exclusion criteria. If after ID approval hours, please contact the ID team the next day for approval between 8 am- 5pm. 

Note, criteria for remdesivir, assessed by ID: 

• • Admitted or roomed in the emergency department with intention to admit
  • Less than or equal to 5 days from symptom onset
  • Positive COVID-19 test
  • Requiring supplemental oxygen (i.e. SpO2 < 94% on room air) excluding high flow, mechanical ventilation and ECMO
  • Limit to five-day course only

• Micromedex
• CareNotes
• UpToDate
• Facts & Comparisons
• MedLinePlus (Patient Information)